Nelson HD. Menopause. Lancet. 2008;371(9614):760–70.
Natari RB, Clavarino AM, McGuire TM, Dingle KD, Hollingworth SA. The bidirectional relationship between vasomotor symptoms and depression across the menopausal transition: a systematic review of longitudinal studies. Menopause. 2018;25(1):109–20.
Schbley BH. Socioeconomic factors in menopausal women’s use of hormone replacement therapy. J Women Aging. 2009;21(2):99–110.
Whiteley J, DiBonaventura M, Wagner JS, Alvir J, Shah S. The impact of menopausal symptoms on quality of life, productivity, and economic outcomes. J Womens Health. 2013;22(11):983–90.
Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33.
Committee TWHIS. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s health initiative randomized controlled trial. JAMA. 2004;291(14):1701–12.
Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, Szklo M. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med. 1993;328(15):1069–75.
Stoppe G, Dören M. Critical appraisal of effects of estrogen replacement therapy on symptoms of depressed mood. Arch Women Ment Health. 2002;5(2):39–47.
Brown S. Shock, terror and controversy: how the media reacted to the Women’s health initiative. Climacteric. 2012;15(3):275–80.
Lawton B, Rose S, McLeod D, Dowell A. Changes in use of hormone replacement therapy after the report from the Women’s Health Initiative: cross sectional survey of users. BMJ. 2003;327(7419):845.
Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, LaCroix AZ, Margolis KL, Stefanick ML. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465–77.
de Villiers TJ, Hall JE, Pinkerton JV, Cerdas Perez S, Rees M, Yang C, Pierroz DD. Revised global consensus statement on menopausal hormone therapy. Climacteric. 2016;19(4):313–5.
Wysowski DK, Governale LA. Use of menopausal hormones in the United States, 1992 through June, 2003. Pharmacoepidemiol Drug Saf. 2005;14(3):171–6.
Sarrel PM, Njike VY, Vinante V, Katz DL. The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59 years. Am J Public Health. 2013;103(9):1583–8.
LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, Margolis KL, Stefanick ML, Brzyski R, Curb JD, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA. 2011;305(13):1305–14.
Bahri N, Pourali L, Esmaeeli H. Application of various menopausal symptoms treatment options and its related factors, Gonabad- 2016. Iran J Obstet Gynecol Infert. 2016;19(26):1–8.
Drewe J, Bucher KA, Zahner C. A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients. Springerplus. 2015;4(1):65.
Goldstein KM, Coeytaux RR, Williams JW Jr, Shepherd-Banigan M, Goode AP, McDuffie JR, Befus D, Adam S, Masilamani V, Van Noord MG. Non-pharmacologic treatments for menopause-associated vasomotor symptoms. Washington DC: DVA Health Services Research and Development Service; 2016.
Carpenter JS, Byrne MM, Studts JL. Factors related to menopausal symptom management decisions. Maturitas. 2011;70(1):10–5.
Siyam T, Carbon J, Ross S, Yuksel N. Determinants of hormone therapy uptake and decision-making after bilateral oophorectomy (BO): a narrative review. Maturitas. 2019;120:68–76.
Hyde A, Nee J, Drennan J, Butler M, Howlett E. Hormone therapy and the medical encounter: a qualitative analysis of women’s experiences. Menopause. 2010;17(2):344–50.
Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Chlebowski RT, Howard BV, Thomson CA, Margolis KL, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the women’s health initiative randomized trials. JAMA. 2017;318(10):927–38.
Langer RD, Hodis HN, Lobo RA, Allison MA. Hormone replacement therapy—where are we now? Climacteric. 2021;24(1):3–10.
Thompson JJ, Ritenbaugh C, Nichter M. Why women choose compounded bioidentical hormone therapy: lessons from a qualitative study of menopausal decision-making. BMC Womens Health. 2017;17(1):97.
Velentzis LS, Banks E, Sitas F, Salagame U, Tan EH, Canfell K. Use of menopausal hormone therapy and bioidentical hormone therapy in Australian women 50 to 69 years of age: results from a national, cross-sectional study. PLoS ONE. 2016;11(3):e0146494.
Bahri N, Sajjadi M, Sadeghmoghadam L. The relationship between management strategies for menopausal symptoms and women’s decision making styles during menopausal transition. Prz Menopauzalny. 2019;18(3):174–9.
Theroux R. Women’s decision making during the menopausal transition. J Am Acad Nurse Pract. 2010;22(11):612–21.
Zapata AML, Beaudreau SA, O’Hara R, Bereknyei Merrell S, Bruce J, Garrison-Diehn C, Gould CE. Information-seeking about anxiety and perceptions about technology to teach coping skills in older veterans. Clin Gerontol. 2017;41(8):346–56.
Kingsberg SA, Schaffir J, Faught BM, Pinkerton JV, Parish SJ, Iglesia CB, Gudeman J, Krop J, Simon JA. Female sexual health: barriers to optimal outcomes and a roadmap for improved patient-clinician communications. J Women’s Health (2002). 2019;28(4):432–43.
Henwood F, Wyatt S, Hart A, Smith J. ‘Ignorance is bliss sometimes’: constraints on the emergence of the ‘informed patient’ in the changing landscapes of health information. Sociol Health Illn. 2003;25(6):589–607.
Pache DM, Hollingworth SA, van Driel ML, McGuire TM. Does consumer medicines interest reflect medicines use? An Australian observational study comparing medicines call center queries with medicines use. Res Social Adm Pharm. 2019;15(4):440–7.
Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM, Committee RW. The REporting of studies conducted using observational routinely-collected health data (RECORD) statement. PLoS Med. 2015;12(10):e1001885.
ATC/DDD Index 2017 https://www.whocc.no/atc_ddd_index/
Commonwealth Department of Health and Aged Care, National Key Centre for Social Applications of Geographical Information Systems: Measuring remoteness: Accessibility/Remoteness Index of Australia (ARIA) revised edition: Commonwealth Department of Health and Aged Care; 2001.
Australian Bureau of Statistics: Year book Australia 2012. Canberra: Australian Bureau of Statistics; 2012.
Beasley TM, Schumacker RE. Multiple regression approach to analyzing contingency tables: Post hoc and planned comparison procedures. J Exp Educ. 1995;64(1):79–93.
Bazeley P. Analysing qualitative data: More than ‘identifying themes.’ Malays J Qual Res. 2009;2(2):6–22.
Pines A, Sturdee DW, Birkhäuser MH, Schneider HPG, Gambacciani M, Panay N. IMS updated recommendations on postmenopausal hormone therapy. Climacteric. 2007;10(3):181–94.
Hengen KM, Alpers GW. What’s the risk? Fearful Individuals generally overestimate negative outcomes and they dread outcomes of specific events. Front Psychol. 2019;10:1676.
Loewenstein GF, Weber EU, Hsee CK, Welch N. Risk as feelings. Psychol Bull. 2001;127(2):267–86.
Shapiro M. Media and education of the consumer. Menopause. 2016;23(8):924–7.
Natari RB, McGuire TM, Baker PJ, Clavarino AM, Dingle KD, Hollingworth SA. Longitudinal impact of the Women’s health initiative study on hormone therapy use in Australia. Climacteric. 2019;22(5):489–97.
Crawford SL, Crandall CJ, Derby CA, El Khoudary SR, Waetjen LE, Fischer M, Joffe H. Menopausal hormone therapy trends before versus after 2002: impact of the Women’s health initiative study results. Menopause. 2018;26(6):588–97.
Ettinger B, Wang SM, Leslie RS, Patel BV, Boulware MJ, Mann ME, McBride M. Evolution of postmenopausal hormone therapy between 2002 and 2009. Menopause. 2018;25(11):1306–12.
Kloosterboer SM, McGuire T, Deckx L, Moses G, Verheij T, van Driel ML. Self-medication for cough and the common cold: Information needs of consumers. Aust Fam Physician. 2015;44(7):497–501.
Gartoulla P, Davis S, Worsley R, Bell R. Use of complementary and alternative medicines for menopausal symptoms in Australian women aged 40–65 years. Med J Aust. 2015;203(3):146–146.
de Villiers TJ, Gass MLS, Haines CJ, Hall JE, Lobo RA, Pierroz DD, Rees M. Global Consensus Statement on menopausal hormone therapy. Maturitas. 2013;74(4):391–2.
Huston SA, Jackowski RM, Kirking DM. Women’s trust in and use of information sources in the treatment of menopausal symptoms. Womens Health Issues. 2009;19(2):144–53.